Trials / Completed
CompletedNCT03115619
Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC). |
Timeline
- Start date
- 2017-04-18
- Primary completion
- 2020-01-10
- Completion
- 2020-01-10
- First posted
- 2017-04-14
- Last updated
- 2020-08-21
Locations
7 sites across 1 country: Greece
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03115619. Inclusion in this directory is not an endorsement.